Eli Lilly plans to pay up to $7 billion to purchase Kelonia Therapeutics

Eli Lilly, a U.S. pharmaceutical corporation, and Kelonia Therapeutics, a privately held biotechnology business. Reached an agreement on Monday to purchase Kelonia Therapeutics for up to $7 billion. Lilly will expand its line of oncology products and have access to experimental cancer medicines thanks to this agreement.

The acquisition is a part of Lilly’s larger plan to lessen its dependence on its obesity sector. In the face of intensifying competition in the market for weight-loss medications. The pharmaceutical giant is purchasing companies creating treatments for inflammatory bowel disease, eye problems, and gene editing.

As Lilly looks to increase its market share in the quickly expanding but fiercely competitive cancer treatment industry. This acquisition is anticipated to bolster the company’s oncology portfolio, which includes the blood cancer therapy Jaypirca. The breast cancer medication Verzenio, and other oncology candidates in development.

Global spending on cancer medications is expected to increase from roughly $223 billion in 2023 to $409 billion in 2028, according to data from IQVIA.

Kelonia shareholders will get up to $7 billion in cash under the terms of the agreement. With an initial payment of $3.25 billion and future payments based on clinical, regulatory, and commercial milestones.

According to Huynh, the $3.25 billion first payment may appear costly, but the competitiveness of the industry’s operations and the quality of the clinical data justify the cost.

Bristol Myers Squibb paid $1.5 billion for Orbital Therapeutics last year, despite the latter’s lack of similar efficacy data at the time. While its rival AbbVie spent $2.1 billion for Capstan Therapeutics, Huynh continued.